Anorgasmia from Clomipramine in Obsessive-Compulsive Disorder

1987 ◽  
Vol 151 (1) ◽  
pp. 107-112 ◽  
Author(s):  
W. O. Monteiro ◽  
H. F. Noshirvani ◽  
I. M. Marks ◽  
P.T. Lelliott
Keyword(s):  
Side Effects ◽  
Sexual Function ◽  
Obsessive Compulsive Disorder ◽  
Structured Interview ◽  
Controlled Study ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Men And Women ◽  
Compulsive Disorder ◽  
Sexual Side Effects

Forty-six patients with obsessive-compulsive disorder undergoing a double-blind controlled study of clomipramine and placebo were interviewed to assess changes in sexual function. Of 33 patients with previously normal orgasm, nearly all of the 24 on clomipramine developed total or partial anorgasmia; none of the 9 on placebo did so. Anorgasmia persisted with minimal tolerance over the five months that clomipramine was taken. Men and women were equally affected. Sexual side-effects are easily missed without a structured interview, and can detract from the value of drug treatment.

Escitalopram in Obsessive-Compulsive Disorder: Response of Symptom Dimensions to Pharmacotherapy

CNS Spectrums ◽  
2008 ◽  
Vol 13 (6) ◽  
pp. 492-498 ◽  
Author(s):  
Dan J. Stein ◽  
Paul D. Carey ◽  
Christine Lochner ◽  
Soraya Seedat ◽  
Naomi Fineberg ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Treatment Response ◽  
Obsessive Compulsive Disorder ◽  
Exploratory Factor Analysis ◽  
Subscale Score ◽  
Controlled Study ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Symptom Dimensions ◽  
Compulsive Disorder

ABSTRACTIntroduction:There is a substantial body of evidence that obsessive-compulsive disorder (OCD) symptoms can be grouped into a series of discrete dimensions, and some evidence that not all OCD symptom dimensions respond equally well to pharmacologic or psychotherapeutic intervention. The response of OCD symptom dimensions to 12 weeks of treatment with escitalopram or placebo was investigated.Methods:Data from a randomized, double-blind, placebo-controlled study of escitalopram in 466 adults with OCD were analyzed. Exploratory factor analysis of individual items of the Yale-Brown Obsessive-Compulsive Scale checklist was performed and subscale scores based on the extracted factors were determined. Analyses of covariance were undertaken to determine whether inclusion of each subscale score in these models impacted on the efficacy of escitalopram versus placebo.Results:Exploratory factor analysis of individual Yale-Brown Obsessive-Compulsive Scale items yielded 5 factors (contamination/cleaning, harm/checking, hoarding/symmetry, religious/sexual, and somatic/hypochondriacal). Analyses of covariance including all the subscales demonstrated that escitalopram was more effective than placebo. There was a significant interaction for the hoarding/symmetry factor, which was associated with a poor treatment response.Conclusion:Escitalopram shows good efficacy across the range of OCD symptom dimensions. Nevertheless, hoarding/symmetry was associated with a poorer treatment response. Hoarding/symmetry may be particularly characteristic of an early-onset group of OCD patients, with the involvement of neurotransmitters other than serotonin. Further work is needed to delineate fully the subtypes of OCD, and their correlates with underlying psychobiology and treatment responsivity.

scholarly journals Buspirone in obsessive-compulsive disorder: a potential dark horse?

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S165-S165
Author(s):  
Kabir Garg ◽  
Himanshu Tyagi
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Safety Profile ◽  
Case Reports ◽  
Controlled Study ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Pharmacological Management ◽  
Double Blind Placebo ◽  
Compulsive Disorder ◽  
Favourable Safety Profile

AimsPharmacological management of Obsessive-Compulsive Disorder (OCD) presents a challenge in modern psychiatry. While most patients respond preferably to serotonin re-uptake inhibitors (SRI), the response is usually delayed by several weeks leading to an insufficient short term management of anxiety. It is also frequently inadequate and needs higher doses and augmentation in many instances. Investigating newer pharmacological strategies to address such treatment gaps has always been of interest. Buspirone is a novel anxiolytic medication with additional weak antidepressant and poor anti-psychotic effects. It is the only medication in its category, i.e. azapriones. It has comparable anti-anxiety efficacy to that of benzodiazepines without their sedating or habit forming effects, and has been demonstrated to moderate serotonin and other monoamine neurotransmission with a favourable safety profile.MethodWe reviewed the literature pertaining to the use of Buspirone in OCD for both as a primary anti-obsessive agent and for a potential secondary role in management of chronic anxiety and/or anxiety disorders comorbid to OCD.ResultThe results of a number of case reports and open trials have been positive while controlled trials have shown contradictory results. In a double blind RCT comparing clomipramine and buspirone, significant improvement was found in both groups with no differences between the two. Further two trials observing buspirone augmentation of clomipramine and fluoxetine treatment respectively, in a double-blind placebo controlled design reported significant improvement in the treatment as opposed to the placebo arm. Another double-blind placebo controlled study of buspirone augmentation of fluvoxamine resistant patients did not show significant benefits as an anti-obsessional agent, but notable anxiolytic effects were reported. In all the trials buspirone was largely well tolerated and did not pose any significant interactions with other psychotropic agents or dependence potential.ConclusionBuspirone is a pharmacologically unique agent with a good safety profile. Given the robust anxiolytic effects of this Peron along with complex neurotransmission modulatory effects coupled with a favourable tolerance and dependents profile might make buspirone an attractive novel pharmacological agent for augmentation in OCD . Further controlled studies to better establish effectiveness and deciphering if certain patients may respond to its use over others, are warranted

Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study

2013 ◽  
Vol 47 (2) ◽  
pp. 175-180 ◽  
Author(s):  
Ali Ghaleiha ◽  
Neda Entezari ◽  
Amirhossein Modabbernia ◽  
Babak Najand ◽  
Neda Askari ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Controlled Study ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Compulsive Disorder
Sign in / Sign up

Export Citation Format

Share Document